Novartis AG at JPMorgan Healthcare Conference Transcript
Welcome to the Novartis presentation at the 41st JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst at JPMorgan. It's my great pleasure to introduce Vas Narasimhan, the CEO of Novartis.
Before I hand over to him for his presentation, I'd just remind you that the -- we will transition after 20 minutes to Q&A in this room, no moving, which is a big round of applause clearly. And there will be microphones. So there'll be people -- so just put up your hand, I'll indicate, and we'll do questions that way. Awesome. Vas, good to see you.
Thank you, Richard. Hi, everyone. Great to be here back in person at JPMorgan. Novartis has a 250-year history. And throughout that history, we've had to constantly reinvent the company. And most recently, when you think about the creation of Novartis 25 years ago in its current format, we were a health care conglomerate with 8 different units, spanning everything from nutritionals and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |